This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $938,470 to the University of Massachusetts Medical School to investigate a novel adipokine that may resolve non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in mouse models. The award period runs from September 1, 2024 to June 30, 2028. The research aims...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $293,543 to Furanica, Inc. to develop a novel compound, FAL-113, for the treatment of nonalcoholic steatohepatitis (NASH). The project aims to determine the mechanism of action, pharmacokinetics, and pharmacological efficacy of FAL-113 in preclinical NASH models. FAL-113 is designed to simultaneously modulate...
The U.S. Department of Health and Human Services' National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $361,400 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Oncotrap Inc. The funding supports the development of a bispecific single-domain antibody targeting the chemokines CCL2 and CCL5 for the treatment of non-alcoholic steatohepatitis (NASH). The award will enable Oncotrap to generate a human version...
This federal Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research at the Pennington Biomedical Research Center to examine the role of the mitochondrial protein SLC25A25 in the onset and progression of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)....
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $172,060 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the role of the unfolded protein response (UPR) in the pathogenesis of non-alcoholic steatohepatitis (NASH). The research aims to understand the mechanism of UPR loss...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $642,653 to the Trustees of Boston University to develop a novel treatment called "Lysogen" for metabolic dysfunction-associated steatotic liver disease (MASLD). The key products and services to be delivered include: Synthesizing and characterizing Lysogen polymers...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Faknostics LLC a $651,952 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop novel peptidic inhibitors targeting the paxillin-FAK (Focal Adhesion Kinase) interaction for the treatment of liver fibrosis. The project aims to optimize lead peptide candidates, characterize their in vitro performance, and confirm efficacy in an animal model of liver...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $594,547 to the University of California, Davis to develop and characterize an orally delivered nanodrug designed to compensate for the shortage of specific microbial metabolite-regulated signaling in liver and colon cancer patients. The nanodrug, named PRORA, combines a histone deacetylase...
This federal Project Grant award of $675,660.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award was granted to the Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct research focused on understanding the regulation and requirements for coenzyme A (CoA) biosynthesis, and how dysregulation of CoA synthesis is related to metabolic diseases...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support the development of a proteomic assay to monitor the success of regenerative medicine therapies involving cell replacement and artificial tissues, such as liver disease treatments. The $175,964 award to Hepatx Corporation will enable the creation of a simple blood test to measure the...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,391,142 to Function Therapeutics Inc. to develop small molecule PAR1 ligands as a novel treatment approach for metabolic dysfunction-associated steatohepatitis (MASH). The project aims to synthesize and evaluate novel "Parmodulin" compounds that can shift PAR1 signaling in liver tissue from a pro-inflammatory to an anti-inflammatory state, with the goal of minimizing liver inflammation and fibrosis associated with MASH. Key activities include medicinal chemistry, in vitro testing, pharmacokinetic studies, and evaluation in a mouse model of advanced MASH. Successful results from this 2-year project could justify future preclinical development of Parmodulins for treating MASH and potentially other liver diseases.